Eikon Therapeutics
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING5
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| EIK1001 NCT06246110 |
P2 | Active, not recruiting | NSCLC | 70 | 2026-12 |
| IMP1734 NCT06253130 |
P1/2 | Recruiting | Advanced Solid Tumor | 156 | 2027-06-01 (+16 mo) |
| EIK1004-001 NCT06907043 |
P1/2 | Recruiting | Advanced Solid Tumors | 130 | 2028-12 (+24 mo) |
| EIK1005 NCT07262619 |
P1/2 | Recruiting | Advanced Solid Tumors; MSI-H or dMMR Advanced Solid Tumors | 160 | 2029-03 |
| EIK1001 NCT06697301 |
P2/3 | Recruiting | Advanced Melanoma | 740 | 2035-12 |
| TeLuRide-008 NCT07365319 |
P2/3 | Recruiting | Non Small Cell Lung Cancer (Squamous or Non Squamous); Stage 4 NSCLC | 750 | 2035-12-31 |